CSF biomarkers in different phenotypes of Parkinson disease
- First Online:
- Cite this article as:
- Jellinger, K.A. J Neural Transm (2012) 119: 455. doi:10.1007/s00702-011-0736-0
- 187 Downloads
CSF biomarker studies were performed in 6 patients each with tremor-dominant (TD) and non-tremor-dominant (NT) Parkinson disease (PD) patients, 27 Alzheimer disease (AD) and 17 age-matched controls. In both NT-PD and AD patients total tau levels and the cortex tau/Aβ-42 were significantly increased compared to both TD-PD patients and controls (p < 0.01). These data in a small cohort confirm previous studies, corroborating the opinion that CSF levels of tau protein and the index total-tau/Aβ-42 may be potential markers of the severity of neurodegeneration in PD.